Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine for ECT-induced cognitive disorders
IRCT20200122046225N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in electroconvulsive therapy-associated cognitive impairment (ECT-ICI) comparing Rivastigmine arm with Placebo arm (2 arms). Primary endpoint: Cognitive function after ECT. Started Sep 2020; status: completed.
02
Drugs
rivastigmine
03
Conditions
electroconvulsive therapy-associated cognitive impairment (ECT-ICI)
Beyond the preview
Go deeper on IRCT20200122046225N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200122046225N1.